1. Generics Bulletin
  2. >>Products

AZ: US Federal Circuit 'Flagrantly Violated Precedent' On Symbicort

Federal Circuit Had Last Month Vacated Stipulated Judgment Of Infringement

 
• By Dean Rudge

The US Court of Appeals for the Federal Circuit has “abandoned the basic principles of significant figures that have long been recognized by this court,” AstraZeneca argues, as part of its petition to have reheard a recent verdict favoring Mylan on the originator’s Symbicort IP.

Federal Circuit closeup_683614828_1200.jpg
The Federal Circuit issued its verdict at the end of last year • Source: Shutterstock

Viatris’Mylan may face a battle to hold onto a recent favorable verdict from the US Court of Appeals for the Federal Circuit that breathed new life into the firm potentially circumventing AstraZeneca’s intellectual property shielding its blockbuster Symbicort (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler.

The UK-based originator has petitioned the Federal Circuit for panel rehearing or rehearing en banc of its recent 2-1 split decision vacating and remanding Viatris’ earlier stipulated

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products